Drug intelligence / Profile preview

VVZ-N3

Development stage: Preclinical
Lead developer: Vivozon
Modality: Small Molecules
Administration: Oral

Overview

VVZ-N3 is an orally administered small molecule drug candidate being developed by Vivozon and its affiliate Vivozon Pharmaceuticals for the treatment of schizophrenia. Discovered using Vivozon's proprietary multi-target platform, VVZ-N3 is designed as a potential best-in-class antipsychotic agent. The drug is currently in the discovery and preclinical stages of development, with Vivozon actively pursuing global partnerships and technology transfer agreements.

Beyond the preview

Go deeper on VVZ-N3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VVZ-N3.

Explore the full profile